GET DAILY SIGNALSShattuck Labs (STTK): What to Expect from the Upcoming Q3 2026 Earnings
Key Takeaways
- Shattuck Labs (STTK) is expected to report its third-quarter 2026 results around November 5–10, 2026, though the exact date has not yet been confirmed by the company.
- Wall Street's consensus calls for a net loss of roughly $0.10 per share, with minimal revenue near $0.03 million.
- In the same quarter last year, the company posted a loss of $0.14 per share on revenue of $1.00 million, so analysts are modeling a narrower loss.
- As a clinical-stage biotechnology company, the headline numbers matter less than updates on the lead drug candidate, SL-172154, and the company's cash runway.
- Shattuck Labs has beaten consensus EPS estimates in six of its last eight quarters, a trend investors will watch closely this time around.
Why This Earnings Report Matters
Shattuck Labs is a clinical-stage biotechnology company developing bifunctional fusion proteins, a class of biologic medicines designed to treat cancer and autoimmune disease. Its wholly owned lead program, SL-172154, is engineered to simultaneously block the CD47/SIRPα checkpoint and activate the CD40 co-stimulatory receptor. Because the company generates little or no product revenue, its quarterly report serves primarily as a progress check on clinical development and capital efficiency. Investors will look past the raw loss figure and focus on trial enrollment, data timing, and how much cash remains on the balance sheet. With expenses narrowing in recent quarters, this update offers a key window into whether management is extending its runway while advancing its pipeline.
Analyst Expectations for the Quarter
Analysts expect Shattuck Labs to report a net loss of approximately $0.10 per share for the third quarter of 2026, with individual estimates ranging from a loss of $0.16 to a loss of $0.08 per share. Consensus revenue is minimal, near $0.03 million, reflecting the company's pre-commercial stage. By comparison, Shattuck Labs reported a loss of $0.14 per share on revenue of $1.00 million in the third quarter of 2025.
In its most recent quarter, the company posted a loss of $0.12 per share, narrowly beating consensus, and it has exceeded EPS estimates in six of the last eight quarters. For a development-stage biotech, investors will likely pay more attention to research and development (R&D) spending, general and administrative costs, and any guidance on cash runway than to the bottom-line figure itself. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Sentiment Heading Into the Report
Sentiment heading into this report leans cautiously optimistic. Analysts maintain a consensus "Strong Buy" rating on Shattuck Labs, with an average 12-month price target well above the stock's recent trading range, reflecting confidence in the company's pipeline rather than its near-term financials. That said, clinical-stage biotech names tend to experience outsized volatility around earnings because the accompanying commentary can signal changes in trial timelines or capital needs. Key risks heading into the print include any indication of a slower-than-expected data readout for SL-172154, higher-than-expected cash burn, or the potential need for additional financing. Investors will be watching for confirmation that the company's cost discipline remains intact and that its cash position is sufficient to reach important clinical milestones.
Forward-Looking Factors to Monitor
Following this report, investors should focus on several forward-looking signals. The first is the progress and timing of the SL-172154 clinical program. Any update on enrollment, dose escalation, or expected data readouts is likely to matter more to the stock than the quarterly loss figure.
The second is cash runway. As a pre-revenue company, Shattuck Labs depends on its cash reserves to fund ongoing trials. Management's commentary on how many quarters of funding remain, and whether additional capital raises may be needed, will be central to the investment case.
Third, watch expense trends. Research and development spending has narrowed in recent quarters, and investors will want to see whether that discipline continues without compromising trial execution. Finally, keep an eye on broader industry dynamics in immuno-oncology and autoimmune therapies, where competitive data readouts from peers can influence sentiment around similar programs. From what I see, the AI Trend Prediction Engine on Tickeron can help track these broader patterns over time.
Tools That Support My Research Process
In my own workflow, I rely on Tickeron’s AI Screener to quickly filter clinical-stage biotechs and compare fundamentals like cash position and R&D trends. It helps surface relevant names and technical setups without spending hours on manual screens, which keeps the focus on the data that actually moves the needle for names like Shattuck Labs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for STTK turns negative, indicating new downward trend
STTK saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 99 similar instances where the indicator turned negative. In 87 of the 99 cases, the stock moved further down in the following days. The odds of a decline are at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for STTK turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 32 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where STTK advanced for three days, in 225 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
STTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.134) is normal, around the industry mean (2.904). P/E Ratio (-10.205) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. STTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement